Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.3392 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CCC(=O)N[C@H](CC1=CNC2=C1C=CC=C2)C(O)=O)C(O)=O
InChI
InChIKey=CATMPQFFVNKDEY-DGCLKSJQSA-N
InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13-/m1/s1
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.3392 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Orilotimod (previously known as Apo 805K1), an antipsoriatic agent that was studied for the treatment of moderate to severe plaque psoriasis. This drug successfully completed phase II clinical trial in the USA. However, information about the further development of this drug is not available.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01483924
Cmax for dosages of 10 mg, 30 mg, 60 mg, or 100 mg Apo805K1 (ORILOTIMOD), determined on Day 14
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:04:25 GMT 2025
by
admin
on
Mon Mar 31 23:04:25 GMT 2025
|
| Record UNII |
Q66Z43C5XM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3137306
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
9909
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
300000034329
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
186087-26-3
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
Q66Z43C5XM
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
AB-03
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
7275810
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY | |||
|
C174870
Created by
admin on Mon Mar 31 23:04:25 GMT 2025 , Edited by admin on Mon Mar 31 23:04:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |